Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung Hyo Sup Shim, MD, PhD, Mari- Kenudson, MD, Zongli Zheng,

Slides:

Advertisements

Similar presentations

Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji.

Advertisements

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma Zoltan Lohinai, MD, Mir Alireza Hoda, MD,

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung Hyo Sup Shim, MD, PhD, Mari- Kenudson, MD, Zongli Zheng,

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk Ping Yang, MD,

Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma Shiyong Li, BS, Yoon-La Choi, MD, PhD, Zhuolin Gong, PhD, Xiao Liu, PhD,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer David R. Gandara, MD,

Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience Ramsey Asmar, MD, Joshua R. Sonett, MD,

Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor Sai F. Yeung, BSc, Joanna H.M. Tong,

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Electronic Updates for JTO Readers

Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients Satu Mäki-Nevala, MSc, Mikko Rönty, MD, Mike Morel, MBiolSci,

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma Zoltan Lohinai, MD, Mir Alireza Hoda, MD,

Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.

Racial Diversity of Actionable Mutations in Non–Small Cell Lung Cancer

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Anya M. Litvak, MD, Paul K. Paik, MD, Kaitlin M. Woo, MS, Camelia S

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Pyrosequencing Analysis of EGFR and KRAS Mutations in EUS and EBUS-Derived Cytologic Samples of Adenocarcinomas of the Lung Jos A. Stigt, MD, Nils A.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging Anya M. Litvak, MD, Kaitlin Woo, MS, Sara Hayes,

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

A Single Institution-Based Retrospective Study of Surgically Treated Bronchioloalveolar Adenocarcinoma of the Lung: Clinicopathologic Analysis, Molecular.

Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non–Small-Cell Lung Cancer with Activating EGFR Mutation Bhumsuk.

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes,

Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell.

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Benjamin Izar, MD, PhD,

Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Bin-Chi Liao,

A Comprehensive Investigation of Molecular Features and Prognosis of Lung Adenocarcinoma with Micropapillary Component Yang Zhang, MD, Rui Wang, PhD,

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Mitotic Inhibitors Journal of Thoracic Oncology

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese.

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

Ernest Nadal, MD, Guoan Chen, MD, PhD, John R

Genetic Changes in Squamous Cell Lung Cancer: A Review

Validity of International Association for the Study of Lung Cancer Proposals for the Revision of N Descriptors in Lung Cancer Jin Gu Lee, MD, Chang Young.

The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

A Functional Polymorphism on Chromosome 15q25 Associated with Survival of Early Stage Non–Small-Cell Lung Cancer Guang Jin, MD, PhD, Eun Young Bae, BS,

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Farhood Farjah, MD, MPH, David R. Flum, MD, MPH, Scott D

Presentation transcript:

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung Hyo Sup Shim, MD, PhD, Mari- Kenudson, MD, Zongli Zheng, PhD, Matthew Liebers, BSc, Yoon Jin Cha, MD, Quan Hoang Ho, BSc, Maristela Onozato, MD, PhD, Long Phi Le, MD, PhD, Rebecca S. Heist, MD, MPH, A. John Iafrate, PhD Journal of Thoracic Oncology Volume 10, Issue 8, Pages 1156-1162 (August 2015) DOI: 10.1097/JTO.0000000000000579 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Mutation distribution for 30 mucinous adenocarcinomas that underwent NGS. All 30 cases were previously determined to be KRAS wild type by targeted methodology. NGS, next generation sequencing. Journal of Thoracic Oncology 2015 10, 1156-1162DOI: (10.1097/JTO.0000000000000579) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Pie charts showing the fraction of mucinous adenocarcinomas that harbor the indicated drivers (A) and the fraction of subtypes of KRAS mutations (B). Journal of Thoracic Oncology 2015 10, 1156-1162DOI: (10.1097/JTO.0000000000000579) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Scatter dot plots for total mutation count between two groups defined by mucinous histology (A), TP53 mutation (B), and smoking status (C) in TCGA lung adenocarcinoma. TCGA, The Cancer Genome Atlas. Journal of Thoracic Oncology 2015 10, 1156-1162DOI: (10.1097/JTO.0000000000000579) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Distribution of mutation counts in TCGA lung adenocarcinoma. Mucinous adenocarcinomas (red) and TP53-mutant cases (blue) are indicated. EGFR-mutant cases (enriched in nonsmokers), KRAS-mutant cases (enriched in smokers), and ALK/ROS1/RET fusions (enriched in nonsmokers) are included as a validation of the data set. TCGA, The Cancer Genome Atlas. Journal of Thoracic Oncology 2015 10, 1156-1162DOI: (10.1097/JTO.0000000000000579) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Survival curves comparing mucinous and nonmucinous cases for overall (A) and recurrence-free (B) survival in stage I–IIIA. Journal of Thoracic Oncology 2015 10, 1156-1162DOI: (10.1097/JTO.0000000000000579) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions